Nuvo Research announces director election results of its Annual General Meeting
May 13 2015 - 5:00PM
PR Newswire (US)
MISSISSAUGA, ON, May 13, 2015 /PRNewswire/ - Nuvo Research
Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse
portfolio of topical and immunology products today announced that
at its 2015 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management
proxy circular dated April 1, 2015
were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
Daniel
Chicoine
|
2,833,962
|
930,810
|
75.28
|
24.72
|
David A.
Copeland
|
3,580,537
|
184,235
|
95.11
|
4.89
|
Anthony E.
Dobranowski
|
3,628,522
|
136,250
|
96.38
|
3.62
|
Dr. Henrich R.K.
Guntermann
|
3,619,959
|
144,813
|
96.15
|
3.85
|
Dr. Klaus von
Lindeiner
|
3,624,109
|
140,663
|
96.26
|
3.74
|
John C.
London
|
3,030,777
|
733,995
|
80.50
|
19.50
|
Dr. Jacques
Messier
|
3,624,625
|
140,147
|
96.28
|
3.72
|
Dr. Theodore H.
Stanley
|
3,627,257
|
137,515
|
96.35
|
3.65
|
About Nuvo Research Inc.
Nuvo (TSX:NRI)
is a specialty pharmaceutical company with a diverse portfolio of
products and technologies. The Company operates two distinct
business units: the Topical Products and Technology (TPT) Group and
the Immunology Group. The TPT Group currently has four
commercial products, a pipeline of topical and transdermal products
focusing on pain and dermatology and multiple drug delivery
platforms that support the development of patented formulations
that can deliver actives into or through the skin. The
Immunology Group has two commercial products and an immune system
modulation platform that supports the development of drug products
that modulate chronic inflammation processes resulting in a
therapeutic benefit. For additional company information visit
www.nuvoresearch.com.
SOURCE Nuvo Research Inc.
Copyright 2015 PR Newswire